The ROE as of September 2024 (TTM) for BridgeBio Pharma, Inc. (BBIO) is 38.59%

According to BridgeBio Pharma, Inc.’s latest financial reports and current stock price. The company's current ROE is 38.59%. This represents a change of 315.48% compared to the average of 9.29% of the last 4 quarters.

BridgeBio Pharma, Inc. (BBIO) Historical ROE (quarterly & annually)

How has BBIO ROE performed in the past?

The mean historical ROE of BridgeBio Pharma, Inc. over the last ten years is -86.68%. The current 38.59% ROE has changed -144.52% with respect to the historical average. Over the past ten years (40 quarters), BBIO's ROE was at its highest in in the March 2021 quarter at 41.26%. The ROE was at its lowest in in the December 2020 quarter at -207.20%.

BridgeBio Pharma, Inc. (BBIO) ROE by Quarter and Year

Discovering the peaks and valleys of BridgeBio Pharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BridgeBio Pharma, Inc. (BBIO) Average ROE

How has BBIO ROE performed in the past?

The current ROE of BridgeBio Pharma, Inc. (BBIO) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

BridgeBio Pharma, Inc. (BBIO) ROE vs. Peers

How is BBIO’s ROE compared to its peers?

BridgeBio Pharma, Inc.’s ROE is greater than IVERIC bio, Inc. (-38.66%), greater than Blueprint Medicines Corporation (-85.25%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Karuna Therapeutics, Inc. (-30.79%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Mirati Therapeutics, Inc. (-81.10%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Apellis Pharmaceuticals, Inc. (-139.02%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), less than PTC Therapeutics, Inc. (57.03%), less than Krystal Biotech, Inc. (13.36%), greater than Intercept Pharmaceuticals, Inc. (-78.24%), greater than Madrigal Pharmaceuticals, Inc. (-95.61%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Inozyme Pharma, Inc. (-68.93%), less than X4 Pharmaceuticals, Inc. (32.93%),

Build a custom stock screener for BridgeBio Pharma, Inc. (BBIO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BridgeBio Pharma, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BridgeBio Pharma, Inc. (BBIO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BridgeBio Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.